Nebenwirkungen · Minjuvi
MINJUVI 200 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-147409 · Präparat HOS-099656
Patients with relapsed or refractory FL after at least one line of systemic therapy The safety of tafasitamab in patients with FL was evaluated in the randomised, double-blind, placebo- controlled multicenter phase 3 study inMIND in 652 patients, including 546 participants with relapsed or refractory (R/R) follicular lymphoma and 106 participants with R/R marginal zone lymphoma. Patients received tafasitamab 12 mg/kg (n = 327) or placebo (n = 325) intravenously in combination with rituximab 375 mg/m2 intravenously (for a maximum of 5 cycles) and lenalidomide 20 mg orally (for a maximum of 12 cycles). Tafasitamab treatment was stopped after 12 cycles. Among patients who received tafasitamab, 83% were exposed for 6 months or longer. The median duration of exposure to tafasitamab was 322 days.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T10:55:00Z · SHA-256 db2a7a79208ec69a20e38f53f43274347a2acea4998641e0c9491f94bc291602 · Passage 7c27aa0216df42ce1eb1b1c8f27cacdc67acba3800563c85973af9d47cc708ce · Zeichen 1393–2194 im Abschnitt